A multinational pharmaceutical company prices a patented oncology therapy at CHF 8,000 per treatment cycle in Switzerland and EUR 4,500 in Spain. A parallel trader identifies the arbitrage opportunity: import Spanish-market product into Switzerland, undercut the official Swiss price, and capture the margin. The Swiss distributor's exclusive distribution agreement appears to prohibit such competition. Whether that prohibition holds depends on questions the distribution agreement may never have addressed: questions about patent coverage, trademark scope, regulatory authorization, and competition law limits that interact differently in Switzerland than in the EU market from which the parallel imports originate.
1. How Does Swiss Exhaustion Work?
Exhaustion doctrine determines when intellectual property rights can no longer prevent resale of goods that the rights holder has already placed on the market. Switzerland maintains a nuanced approach that varies by IP category: regional (EEA) exhaustion for most patents since 2009, national exhaustion for state-price-regulated patents, and international exhaustion for trademarks and designs. This asymmetry creates strategic opportunities, and traps, for pharmaceutical distribution structures.
Since 1 July 2009, Switzerland has operated under regional (EEA) exhaustion for patents under Art. 9a(1)–(3) PatG.1Art. 9a PatG: regional (EEA) exhaustion under 9a(1)–(3) since 2009; international exhaustion where the patent is of subordinate importance under 9a(4); national exhaustion for state-priced goods such as SL-listed medicines under 9a(5). Before 2009, national exhaustion applied (BGE 126 III 129, Kodak). Before that reform, national exhaustion governed patents, the position the Federal Supreme Court had reached in Kodak; the legislature replaced it with EEA-regional exhaustion. Patent rights are exhausted once the patent holder places the product on the market anywhere in the EEA with consent. A narrow further exception, Art. 9a(4) PatG, applies international exhaustion where patent protection is of merely subordinate importance to the product's functional characteristics, a predicate that pharmaceuticals (whose patented active substance is central rather than incidental) rarely satisfy. Switzerland adopted this regional regime unilaterally: Swiss patent holders are exposed to EEA-sourced imports, yet Swiss exports carry no reciprocal exhaustion benefit under EU law. By contrast, Art. 9a(5) PatG retains national exhaustion for goods whose price is fixed by the state, most significantly medicines listed on the Spezialitätenliste (SL) reimbursed by compulsory health insurance. For SL-listed medicines, the patent holder may prevent importation even from EEA markets. For non-SL pharmaceutical products (OTC products, hors-liste medicines, products outside compulsory insurance), regional exhaustion applies and the patent holder cannot block parallel imports from EEA countries.
Switzerland is one of the few markets where a patent can bar parallel imports of a price-regulated medicine even from the EEA, but only for as long as the patent and its supplementary protection survive.
Trademark exhaustion follows a different principle. The Federal Supreme Court's Chanel decision established international exhaustion as the general rule: once trademarked goods are placed on the market anywhere with the trademark owner's consent, the trademark generally cannot prevent their importation into Switzerland.2BGE 122 III 469 (Chanel). This principle is subject to recognized exceptions, particularly where the trademark owner demonstrates "legitimate reasons" to oppose further commercialization, such as material differences between Swiss-market and foreign-market versions or where quality control concerns justify territorial restrictions. The scope and application of these exceptions remains contested in practice.
International trademark exhaustion in Switzerland is not absolute. The Federal Supreme Court has recognized that trademark owners may oppose further commercialization where legitimate reasons exist, terminology that tracks Art. 15(2) of the EU Trade Mark Directive (Directive (EU) 2015/2436) but operates within Swiss autonomous interpretation. Whether this constitutes "modified" international exhaustion or simply the inherent scope of the exhaustion doctrine remains doctrinally contested. The practical effect, however, is clear: parallel import restrictions based on trademark rights require factual predicates that pharmaceutical products may or may not satisfy.
Design rights under the Designgesetz (DesG) are subject to international exhaustion according to prevailing Swiss legal opinion, consistent with the approach for trademarks and copyrights.3Bundesgesetz über den Schutz von Design (Designgesetz, DesG) vom 5. Oktober 2001 (SR 232.12). No explicit exhaustion provision; prevailing doctrine supports international exhaustion (Dessemontet/Kamen; Hilti). While design protection rarely prevents pharmaceutical parallel imports (the underlying API or formulation is typically unprotectable through design rights), distinctive packaging or delivery device aesthetics may provide supplementary protection. The practical significance depends on whether parallel traders must repackage products and thereby potentially infringe design rights that survived exhaustion.
2. What Are the Limits of Patent Protection?
For SL-listed pharmaceutical products with valid Swiss patent protection, national exhaustion under Art. 9a(5) PatG provides a clear statutory basis for blocking parallel imports. The patent holder, or an exclusive licensee with appropriate rights, can seek injunctive relief against importers who source patented products from lower-priced markets. However, for non-SL products, the regional exhaustion framework means patent-based parallel import restrictions are enforceable only against imports from outside the EEA.
The practical limits emerge from patent scope and timing. Pharmaceutical patents eventually expire. Supplementary protection certificates (SPCs) under Art. 140a–140m PatG extend patent-like protection for up to five years beyond basic patent expiry, partially compensating for the time consumed by regulatory approval processes.4Art. 140a–140m PatG (basic SPC); Art. 140n PatG (six-month pediatric extension). SPC regime mirrors Regulation (EC) No 469/2009 but operates autonomously under Swiss law. The SPC covers the specific product as authorized, not the patent's full claim scope. A pharmaceutical patent may cover multiple formulations, but the SPC extends only to products that obtained marketing authorization. Parallel import analysis must therefore track both patent expiry and SPC expiry, which may differ across products within the same therapeutic class. The SPC pediatric extension under Art. 140n PatG may add a further six months for products with approved pediatric indications, creating additional complexity for portfolio-wide distribution agreements. A distinct pediatric supplementary protection certificate under Art. 140t ff. PatG, an instrument unique to Swiss law, can confer protection where no ordinary certificate exists, for instance where the marketing-authorization process ran shorter than five years, so it matters precisely in the cases the ordinary SPC would leave exposed. Once all applicable protection lapses, the national exhaustion shield disappears. A distribution agreement structured around patent-based import restrictions faces a cliff when patents and SPCs expire, often precisely when generic competition makes parallel import arbitrage most attractive to traders.
Biosimilar and generic entry interact with these exhaustion dynamics. Price reductions triggered by competition during periodic SL pricing reviews may narrow the arbitrage that motivates parallel imports, but may also affect whether a product's SL status or pricing structure continues to support the national exhaustion exception under Art. 9a(5) PatG.5Art. 65d ff. KVV; BAG, Handbuch betreffend die Spezialitätenliste (SL) (2024). The proposed EU pharmaceutical legislation revision (COM(2023) 192 and COM(2023) 193), if enacted, could further compress exclusivity timelines, potentially accelerating the emergence of price differentials that drive parallel import pressure into Switzerland.6COM(2023) 192 final; COM(2023) 193 final (proposed revision of EU pharmaceutical legislation).
Patent scope creates additional complexity. A Swiss patent may cover certain formulations but not others. If a parallel trader sources a formulation not covered by Swiss patent claims (perhaps a different dosage strength or delivery mechanism authorized in the source market), the patent provides no barrier. Distribution agreements sometimes assume patent coverage that proves narrower than anticipated when tested against specific parallel import scenarios.
Compulsory licensing presents a theoretical but rarely invoked limitation. Swiss patent law permits compulsory licenses in several defined circumstances, including on public interest grounds and to remedy anti-competitive practices.7Art. 40 ff. PatG (n 1). While pharmaceutical compulsory licenses have not been granted in Switzerland since at least 2000, the mechanism exists. Distribution structures that depend entirely on patent exclusivity carry this residual risk.
3. How Do Trademark and Regulatory Barriers Apply?
When patent protection is unavailable (whether because patents have expired, claims do not cover the specific product, or patents were never obtained), trademark rights become the primary intellectual property tool. Here Switzerland's international exhaustion baseline creates challenges that distribution agreements struggle to overcome. Beyond trademark law, regulatory authorization and data-protection requirements form a second layer of barriers, addressed below alongside the trademark analysis.
The international exhaustion principle established in BGE 122 III 469 permits parallel imports of genuine trademarked goods. A parallel trader importing authentic pharmaceutical products bearing the manufacturer's trademark does not infringe that trademark merely by importing without authorization. The goods are genuine; the trademark's origin function is not impaired. Distribution agreements cannot rely on trademark rights to prevent such imports unless an exception applies.
The recognized exceptions require factual predicates that pharmaceutical products may or may not satisfy. Material differences between Swiss-market and foreign-market versions can justify trademark-based restrictions, but the differences must be material to consumers, not merely administrative. Whether packaging differences, language variations, or regulatory reference numbers constitute "material" differences is highly fact- and product-dependent; courts assess these questions case by case rather than applying categorical rules.8BGE 122 III 469 (n 2). Different formulations, dosage forms, or therapeutic indications present stronger candidates for material difference findings, but even these require demonstration in the specific context.
Quality control arguments provide another potential exception. If the trademark owner can demonstrate that parallel-imported goods may not meet quality standards due to different storage conditions, handling practices, or supply chain integrity issues, trademark protection may extend to blocking such imports. Pharmaceutical cold chain requirements, controlled substance handling protocols, and similar quality-justified restrictions have found support in EU case law and Swiss legal doctrine. But the burden of demonstrating actual quality risk, not merely theoretical concern, falls on the trademark owner seeking to prevent imports.
Regulatory Authorization Barriers
Parallel importers face regulatory as well as intellectual property barriers. Under Art. 9 HMG, placing a medicinal product on the Swiss market requires Swissmedic authorization.9Art. 9 Bundesgesetz über Arzneimittel und Medizinprodukte (Heilmittelgesetz, HMG) vom 15. Dezember 2000 (SR 812.21). Parallel imports of products already authorized in Switzerland may benefit from simplified procedures under Art. 14 HMG and the implementing VAZV, but the importer must still obtain authorization, ensure Swiss-compliant labeling, and maintain pharmacovigilance capabilities. These requirements do not prevent parallel imports but impose costs and delays that reduce arbitrage margins. For products with complex stability requirements, cold chain obligations, or controlled substance classifications, regulatory compliance may prove commercially prohibitive even where intellectual property rights do not apply. Distribution agreements that rely on these regulatory barriers, rather than intellectual property, face the risk that Swissmedic may streamline import procedures or that parallel traders may develop compliant supply chains.
Document protection (Unterlagenschutz) under the HMG provides a further regulatory barrier distinct from patent or trademark protection.10Art. 11a HMG (n 9) (ten-year Unterlagenschutz for new active substances, granted ex officio; three years for a new indication, route, form, or dosage); Art. 11b HMG (n 9) (fifteen years for important orphan medicines, ten for exclusively pediatric use or a significant new indication); Art. 12 HMG (n 9) (authorization of essentially identical medicines after data exclusivity expiry). The originator's authorization dossier is protected for ten years (extended to fifteen for important orphan medicines under Art. 11b HMG), a period during which a generic or biosimilar applicant seeking simplified authorization under the VAZV cannot rely on the originator's clinical data. This exclusivity operates independently of patent status, potentially blocking new market entrants even after patent expiry. Parallel imports of products already authorized in Switzerland are not directly blocked by Unterlagenschutz, but the interaction between data exclusivity timelines and simplified authorization pathways shapes the competitive landscape within which parallel import economics operate.
A separate liability dimension shadows parallel trade into EU and EEA markets. Under the revised EU Product Liability Directive (Directive (EU) 2024/2853), an operator that imports a product into the EU or EEA bears manufacturer-equivalent liability for defective products,11Directive (EU) 2024/2853 on liability for defective products [2024] OJ L 2024/2853, repealing Directive 85/374/EEC. exposure that falls on parallel traders precisely because they hold no contractual relationship with the manufacturer whose goods they move.
Repackaging and Relabeling
A central practical question is under what conditions a parallel trader may repackage or relabel products for the Swiss market. EU case law (the BMS v Paranova line of decisions) has established detailed conditions under which repackaging does not infringe trademark rights, addressing necessity, product integrity, manufacturer identification, reputation, and prior notice.12Joined Cases C-427/93, C-429/93, C-436/93, Bristol-Myers Squibb v Paranova [1996] ECR I-3457; Case C-348/04, Boehringer Ingelheim v Swingward [2007] ECR I-3391. Swiss law has no direct equivalent. The practical consequence is that Swiss parallel traders operate with less doctrinal certainty than their EU counterparts, who can at least calibrate their conduct against the settled BMS conditions. The question arises instead at the intersection of trademark exhaustion exceptions and Swissmedic labeling requirements: a parallel trader who must repackage to comply with Swiss packaging rules but thereby risks impairing the trademark's origin function faces a dilemma that the exhaustion doctrine does not cleanly resolve.
Trademark-based restrictions thus depend on factual predicates that require case-specific demonstration. Even where those predicates exist, competition law imposes independent constraints, constraints that operate regardless of whether intellectual property rights would independently support the challenged restrictions.
4. What Competition Law Constraints Apply?
Even where intellectual property rights might support parallel import restrictions, Swiss competition law imposes independent constraints on distribution agreement structures. The Kartellgesetz prohibits agreements that significantly restrict competition unless efficiency justifications or de minimis exceptions apply.13Art. 5 Bundesgesetz über Kartelle und andere Wettbewerbsbeschränkungen (Kartellgesetz, KG) vom 6. Oktober 1995 (SR 251).
Territorial restrictions in distribution agreements receive particular scrutiny. An exclusive distribution agreement that prohibits the Swiss distributor from selling outside Switzerland, or that prohibits the manufacturer from supplying other Swiss purchasers, constitutes a vertical agreement that may restrict competition. Switzerland does not have a block exemption regulation for vertical agreements analogous to the EU framework. The Competition Commission (Wettbewerbskommission, WEKO) has, however, issued the Bekanntmachung über die wettbewerbsrechtliche Behandlung vertikaler Abreden (Vertikalbekanntmachung), which provides a structured analytical framework for assessing distribution arrangements.14WEKO, Vertikalbekanntmachung (12 December 2022); cf Commission Regulation (EU) 2022/720 [2022] OJ L134/4 (VBER).
The Vertikalbekanntmachung distinguishes between hard-core restrictions that are presumed to restrict competition significantly and softer vertical restraints assessed under a market-share framework. Hard-core restrictions include absolute territorial protection, meaning clauses that prohibit a distributor from responding to unsolicited orders from outside the assigned territory (passive sales restrictions), and absolute export bans. These are treated as qualitatively significant restrictions regardless of market share. By contrast, vertical restraints that do not constitute hard-core restrictions are generally presumed not to restrict competition significantly where the supplier's and the buyer's market shares each fall below 30 percent, and where no cumulative effects from parallel networks of similar agreements are present.
For pharmaceutical distribution agreements, the critical question is whether clauses designed to prevent parallel imports constitute absolute territorial protection (hard-core) or permissible qualitative selectivity criteria. The answer often turns on whether the restriction operates by prohibiting sales to certain buyers or to certain territories, a distinction that may be formal rather than substantive when the practical effect is the same.
WEKO has examined pharmaceutical distribution arrangements in multiple proceedings.15See, e.g., WEKO, Sanphar, RPW 2001/1; Hors-Liste Medikamente, RPW 2010/4, p. 649; cf Gaba International AG, RPW 2010/1, p. 99 (confirmed BGE 143 II 297); Nikon AG (28 Nov 2011), confirmed BVGer B-581/2012 of 16 Sept 2016. The leading authorities outside the pharmaceutical sector, the Federal Supreme Court's Gaba ruling and the Nikon proceeding, confirm the governing principle: clauses conferring absolute territorial protection, including measures that obstruct parallel imports, count as hard-core restraints presumed to restrict competition significantly irrespective of market share. In at least one examined proceeding, WEKO distinguished between restrictions that foreclose parallel trade entirely and those that merely structure authorized distribution channels. Export prohibitions imposed on Swiss distributors have attracted scrutiny, particularly where they appear designed to maintain price differentials between Switzerland and lower-priced markets, though the limited published case law leaves the precise contours of WEKO's enforcement approach in the pharmaceutical sector less predictable than in other industries.
The interaction between intellectual property rights and competition law creates interpretive complexity. A manufacturer may lawfully enforce patent rights against parallel imports; patent enforcement does not typically constitute an abuse of dominance or unlawful agreement. But contractual provisions that extend beyond what patent rights provide, or that operate after patent expiry, face competition law assessment on their own terms. A distribution agreement that attempts to achieve through contract what intellectual property law does not provide may constitute an unlawful restriction.
Unfair competition law adds a further dimension. Art. 3 of the Bundesgesetz gegen den unlauteren Wettbewerb (UWG) can be relevant where parallel import activity involves misleading consumers about the source or quality of products, for instance where repackaged or relabeled goods create confusion about the responsible manufacturer or marketing authorization holder.16Art. 3(1)(d) UWG (measures causing confusion); Art. 2 UWG (general clause on unfair commercial practices). Arguments that a parallel trader free-rides on the originator's distribution investments or marketing expenditure may also engage the UWG's general clauses on unfair commercial practices. While UWG claims rarely succeed as standalone barriers to parallel trade (the Federal Supreme Court has been reluctant to use unfair competition law to override the exhaustion doctrine's market-opening function), they provide an additional layer that may reinforce IP-based restrictions where the parallel importer's practices create genuine quality or sourcing confusion.
Selective Distribution Systems
Selective distribution offers a potential framework for controlling distribution channels without running afoul of competition law prohibitions on territorial restrictions. Under a qualitative selective distribution system, the manufacturer sells only to distributors meeting objective quality criteria (facilities, training, service capabilities) without imposing territorial limitations on where authorized distributors may resell.
Pharmaceutical distribution involves requirements (GDP-compliant storage, pharmacovigilance capabilities, regulatory notification obligations) that lend themselves to qualitative selection criteria. Such criteria can legitimately exclude distributors who lack the infrastructure to handle pharmaceutical products safely, including parallel traders without established pharmaceutical logistics. The range of potentially qualifying criteria is broad, and designing a system that is both commercially effective and legally defensible requires careful calibration.
The criteria must be objective, uniformly applied, and proportionate to legitimate quality objectives. Criteria designed primarily to exclude parallel traders rather than to ensure quality will not survive competition law scrutiny, and the line between the two is assessed by reference to actual application, not stated intent. Competition authorities have historically viewed pharmaceutical selective distribution with skepticism, and demonstrating that quality criteria serve genuine patient safety objectives rather than market partitioning requires careful documentation and consistent enforcement across all distributors.
5. What Should Distribution Agreements Address?
Distribution agreements for Swiss pharmaceutical markets operate within constraints that differ substantially from EU structures. For SL-listed medicines, the national exhaustion exception under Art. 9a(5) PatG provides protection unavailable in the EU, but only while patents remain in force and only for products within patent scope. For non-SL products, regional exhaustion applies, and patent-based blocking is limited to non-EEA sources. Trademark protection offers less than some agreements assume. Competition law limits what contracts can achieve independent of intellectual property rights.
The difficulty is that these dimensions interact differently for different products within the same portfolio. A product with valid Swiss patent protection, SL listing, and material differences between Swiss-market and foreign-market versions may be well protected against parallel imports through multiple overlapping mechanisms. The same manufacturer's off-patent, non-SL product with identical formulations across markets may be virtually unprotectable. Portfolio-wide exclusivity clauses that assume uniform coverage cannot accommodate this variation and may prove enforceable for some products while creating competition law exposure for others, particularly where contractual restrictions extend beyond what intellectual property rights independently support.
The interrelationship between patent expiry, trademark enforceability, and selective distribution design compounds this complexity. When patent protection lapses (including SPC and pediatric extensions), the distribution agreement's protective logic must shift from exclusion-based mechanisms to quality-based selective distribution criteria and trademark exceptions. Whether those alternative mechanisms are available depends on factual predicates established before the transition occurs: material product differences must be documented, selective distribution criteria must already be operational and uniformly applied, and regulatory barriers must be genuine rather than pretextual. Agreements that defer these questions until patent expiry arrives may find that the groundwork was never laid.
Several drafting choices follow. Restrictions are better tied to each product's specific protection status through per-product schedules than asserted uniformly across a portfolio, so that a clause cannot be attacked as overreaching for the products it does not legitimately cover. Sunset and trigger provisions can align contractual restrictions with the expiry of patents, supplementary protection, and any pediatric extension or certificate, and with changes in SL status, rather than leaving a restriction standing after its legal foundation has lapsed. Where exclusion-based protection will eventually fall away, a qualitative selective-distribution framework built on objective GDP criteria offers a defensible fallback, provided it is operational and uniformly applied before it is relied upon. Export prohibitions directed at Swiss distributors are best avoided altogether, given that the Gaba and Nikon authorities treat them as hard-core restraints. The factual predicates for trademark exceptions, namely material product differences and genuine quality-control concerns, warrant documentation in advance rather than assertion after a parallel trader has appeared.
These questions do not resolve through standard contract language. Each product, market, and competitive situation presents a distinct combination of intellectual property coverage, regulatory status, and commercial dynamics, with consequences that emerge only when parallel traders test the assumptions.